FDA Clearance Tracker · P180002-S019
Zephyr Endobronchial Valve (Zephyr Valve)
Last checked: Nov 20, 2026Latest source record: Aug 13, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Aug 13, 2021
Approved
Time to decision
28 days
Received Jul 16, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P180002-S019
- Device name
- Zephyr Endobronchial Valve (Zephyr Valve)
- Applicant
- Pulmonx Corporation
- Applicant location
- Redwood City, CA
- Received
- Jul 16, 2021
- Decided
- Aug 13, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P180002
Device type
- Device type
- Valve, pulmonary (NJK)
- Device class
- Class III
- Specialty
- Anesthesiology & Respiratory
FDA's approval statement
As written in FDA's record.
Approval for modifications to the protocol to include collection of perfusion data at baseline, extension of high-resolution computed tomography (HRCT) baseline data collection window from 3 months to 6 months prior to Informed Consent date, and collection of HRCT data at 12 months.
Source documents
Other decisions for Pulmonx Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K253096 · Decided Feb 13, 2026 · 143 days after receipt
Device type: Tube, Tracheal/Bronchial, Differential Ventilation (W/Wo Connector) (CBI) · Anesthesiology & Respiratory
K222340 · Decided Dec 1, 2022 · 120 days after receipt
Device type: Tube, Tracheal/Bronchial, Differential Ventilation (W/Wo Connector) (CBI) · Anesthesiology & Respiratory
- Lung Image AnalysisThird-party review510(k)
K212494 · Decided Sep 2, 2021 · 24 days after receipt
Device type: System, X-Ray, Tomography, Computed (JAK) · Radiology & Imaging
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.